Vor Bio (VOR) announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg. The data, which was presented in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback